Comparative study between intralesional injection of MMR, BCG, and candida albicans antigen in treatment of multiple recalcitrant warts
RM Eldahshan, WMO Ashry… - Journal of Cosmetic …, 2022 - Wiley Online Library
Journal of Cosmetic Dermatology, 2022•Wiley Online Library
Background Cutaneous warts represent a challenging condition to treat. Objective To
evaluate the safety and efficacy of intralesional injection of MMR (mumps, measles, and
rubella) antigen, BCG (bacillus Calmette‐Guerin) vaccine, and candida antigen for the
treatment of multiple warts. Methods A total of ninety (90) clinically confirmed adult patients
complaining of recalcitrant extragenital warts of various sizes and durations were recruited
in this randomized clinical trial. They were divided into three groups (A, B, and C). Each …
evaluate the safety and efficacy of intralesional injection of MMR (mumps, measles, and
rubella) antigen, BCG (bacillus Calmette‐Guerin) vaccine, and candida antigen for the
treatment of multiple warts. Methods A total of ninety (90) clinically confirmed adult patients
complaining of recalcitrant extragenital warts of various sizes and durations were recruited
in this randomized clinical trial. They were divided into three groups (A, B, and C). Each …
Background
Cutaneous warts represent a challenging condition to treat.
Objective
To evaluate the safety and efficacy of intralesional injection of MMR (mumps, measles, and rubella) antigen, BCG (bacillus Calmette‐Guerin) vaccine, and candida antigen for the treatment of multiple warts.
Methods
A total of ninety (90) clinically confirmed adult patients complaining of recalcitrant extragenital warts of various sizes and durations were recruited in this randomized clinical trial. They were divided into three groups (A, B, and C). Each group consisted of (30) patients. Group (A) subjects received intralesional MMR injections. Group (B) subjects received intralesional BCG injection and Group (C) received intralesional candida antigen injection.
Results
Full clearance of warts was observed in (73.33%, 70%, and 43.33%) in groups A, B, and C, respectively. Infrequent side effects including pain, erythema, and minimal induration were reported in all groups but did not necessitate termination of treatment.
Conclusion
All the three modalities used demonstrated a simple, safe modality with low adverse events, and with no recurrence. To achieve an optimal response with an ideal immunotherapeutic agent and ideal dose, further comparative studies are warranted and on different populations and larger sample sizes.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果